Investigators highlighted that when determining a treatment strategy for patients with early-stage prostate cancer, baseline benign prostate hyperplasia symptoms should be taken into consideration.
To provide the best therapy decision making for patients with early-stage prostate cancer, investigators stated that benign prostatic hyperplasia (BPH) symptoms at baseline should be considered, according to a study published in BMC Urology.
The Expanded Prostate Cancer Index Composite-50 (EPIC-50) scores were found to have declined significantly 5 weeks following surgery and recovered to either near or below baseline at 12 months. Moreover, some patients experienced an improvement past baseline in each subscale ranging from 3.3% to 51.0%. At baseline, patients who had benign BPH—defined by a prostate size of 40 g or more, an International Prostate Symptom Index Score of 8 or more, or use of BPH medications—had an improvement in outcomes following surgery, including voiding dysfunction bother at 5 weeks (OR, 3.9; 95% CI, 2.1-7.2) and 12 months (OR, 3.3; 95% CI, 2.0-5.7).
A total of 426 patients were eligible to complete the survey, of whom 395 provided EPIC-50 sub-scale data at baseline, 5 weeks, or 12 months. Of the patients enrolled, 167 had Charlson Comorbidity Index data and 103 had at least 1 comorbidity. Patient characteristics indicated that 78.5% of patients had clinical stage T1 disease and 88.9% had T3 with pre-surgical prostate-specific antigen concentration between 4 ng/mL and 10 ng/mL. Minimally invasive radical proctectomy was performed in 92.3% and 65.2% had bilateral nerve-sparing procedure.
At baseline, the majority of patients had a high urinary incontinence function (mean = 93.1) and bother scores (mean = 95.8), as well as voiding dysfunction-related bother (mean = 74.5). However, scores at baseline were lower for incontinence-related bother and urinary outcomes were also low. Patients had a lower score in relation to sexual outcomes (mean = 56.2) and bother (mean = 68.9) at baseline.
Outcomes notably decreased 5 weeks following surgery. At 6 months following surgery, incontinence-related outcome scores had increased to near but below baseline before evening out at 12 months. Additionally, voiding dysfunction related-bother levels recovered to above baseline levels at 6 months and remained consistent through 12 months. Mean baseline levels remained below baseline in terms of sexual-related outcomes but appeared to slowly improve through the 12-month post-surgical period.
Voiding dysfunction-related bother scores saw the most significant improvement from 22.1% of patients at 5 weeks vs 50.9% at 12 months, followed by sexual bother at 7.3% at 5 weeks vs 10.6% at 12 months, and urinary function at 9.8% at 12 months. Less than 5% of patients experienced improvement in incontinence-related bother and sexual function.
Investigators reported that individual measures of BPH and BPH composite measure were associated with an improvement in 5-week and 12-month post-surgical voiding dysfunction-related bother (odds ratio [OR], 3.9; 95% CI, 2.1-7.2) and 12 months (OR, 3.3; 95% CI, 2.0-5.7). Moreover, investigators did not identify any associations between erectile dysfunction medication, device use at baseline, or follow-up. Additionally, no significant associations between BPH and erectile dysfunction factors, and improved/maintained sexual function. BPH composite score was associated with improved sexual bother at 5 weeks (OR, 5.7; 95% CI, 1.7-19.3) and 12 months (OR, 3.0; 95% CI, 1.2-7.1).
Several individual measure of BPH including use of α-blocker had positive associations (OR, 4.4; 95% CI, 1.1-18.0) with improved sexual function at 12 months and BPH medication use (OR, 5.4, 95% CI; 2.2–13.0) and α-blocker use (OR, 5.6, 95% CI; 2.2–14.6) and improvement in sexual bother at 5 weeks. Erectile dysfunction medication use had an inverse association with sexual function (OR, 0.5, 95% CI; 0.3–0.9) and bother (OR, 0.5, 95% CI; 0.3–1.0) compared with 12 months post-surgery.
Yang L, Lee JA, Heer E, et al. One-year urinary and sexual outcome trajectories among prostate cancer patients treated by radical prostatectomy: a prospective study. BMC Urol. Published May 17, 2021. doi:10.1186/s12894-021-00845-0
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.